Gilead Sciences awards $2.5 million to CWRU AIDS Clinical Trials Unit
February 1, 2017: Gilead Sciences awarded CWRU School of Medicine’s Michael M. Lederman, MD to study HIV Reservoir Reduction with Interleukin-2 and monoclonal antibody treatments. IL-2 and certain monoclonal antibodies have been shown separately to reduce the presence of HIV, but have not been studied together as a potential cure.
www.newswise.com/articles/can-a-novel-combination-of-treatments-help-eradicate-hiv